|
Variable
|
Overall (n = 15)
|
Initial therapy (n = 7)
|
Second-line therapy (n = 8)
|
P value
|
|---|
|
Age (years)
|
62 (45–67)
|
52 (39–62)
|
64 (57–67)
|
0.12
|
|
Female
|
8 (53)
|
5 (71)
|
3 (38)
|
0.32
|
|
Systolic BP (mmHg)
|
140 (124–148)
|
124 (114–140)
|
147 (135–164)
|
0.037
|
|
Diastolic BP (mmHg)
|
82 (72–86)
|
80 (67–86)
|
83 (79–89)
|
0.29
|
|
Serum Creatinine (mg/dL)
|
1.2 (0.8–1.5)
|
0.8 (0.5–0.9)
|
1.3 (1.2–2.1)
|
0.011
|
|
eGFR (ml/min/1.73 m2)
|
65 (40–100)
|
100 (62–123)
|
56 (29–66)
|
0.024
|
|
eGFR Group
| | | |
0.45
|
|
> 60 ml/min/1.73 m2
|
10 (67)
|
6 (86)
|
4 (50)
| |
|
30–60 ml/min/1.73 m2
|
3 (20)
|
1 (14)
|
2 (25)
| |
|
< 30 ml/min/1.73 m2
|
2 (13)
|
0 (0)
|
2 (25)
| |
|
UPCR (g/g)
|
8.2 (6.8–11.4)
|
6.9 (5.2–10.2)
|
10.1 (8.0–11.7)
|
0.15
|
|
UPCR group
| | | |
0.41
|
|
< 4a
|
1 (7)
|
1 (14)
|
0 (0)
| |
|
4–8
|
5 (33)
|
3 (43)
|
2 (25)
| |
|
> 8
|
9 (60)
|
3 (43)
|
6 (75)
| |
|
Nephrotic Syndromeb
|
13 (87)
|
7 (100)
|
6 (75)
|
0.47
|
|
Albumin (g/dL)
|
2.7 (2.5–2.8)
|
2.7 (2.5–2.8)
|
2.6 (2.4–3.1)
|
0.86
|
|
Total Cholesterol (mg/dL)c
|
350 (252–371)
|
341 (252–367)
|
371 (249–438)
|
0.34
|
|
Triglycerides (mg/dL)c
|
172 (122–270)
|
134 (77–192)
|
177 (155–546)
|
0.14
|
|
Time Since Biopsy Diagnosis (months)
|
9 (3–24)
|
3 (0.5–4)
|
23 (16–60)
|
0.011
|
|
On ACE-I or ARB
|
13 (87)
|
5 (71)
|
8 (100)
|
0.20
|
|
On Statin
|
8 (53)
|
2 (29)
|
6 (75)
|
0.13
|
|
Treatment Indications
| | | | |
|
Failure of ACE-I or ARBd
|
8 (53)
|
2 (29)
|
6 (75)
|
0.13
|
|
Declining Renal Function
|
5 (33)
|
1 (14)
|
4 (50)
|
0.30
|
|
Debilitating Symptoms from nephrotic syndrome
|
10 (67)
|
5 (71)
|
5 (63)
|
0.99
|
|
Relapsing Disease
|
6 (38)
|
NA
|
6 (75)
|
NA
|
|
Refractory Disease
|
3 (19)
|
NA
|
3 (38)
|
NA
|
- Data are presented as median (interquartile range) and n (%)
-
Abbreviations: ACE-I angiotensin converting enzyme, ARB angiotensin receptor blocker, BP blood pressure, eGFR estimated glomerular filtration rate, UPCR urinary protein: creatinine ratio
-
aThe patient with a UPCR < 4 g/g had decompensated nephrotic syndrome with refractory edema and an albumin nadir of 1.1 g/dL
-
bNephrotic syndrome was defined as urinary protein: creatinine ratio > 3.5 g/g, serum albumin < 3 g/dL, and peripheral edema
-
cOne patient in the second-line therapy group did not have baseline cholesterol or triglycerides
-
dFailure of ACE-I or ARB was defined as a persistent UPCR > 4 g/g despite at least 6 months of therapy
